表紙
市場調査レポート

点眼薬:データ・分析・予測

Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

発行 GMR Data Ltd 商品コード 301555
出版日 ページ情報 英文 151 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
点眼薬:データ・分析・予測 Ophthalmic Drugs; Data, Analysis and Forecasts to 2024
出版日: 2014年03月04日 ページ情報: 英文 151 Pages
概要

世界の眼科治療薬市場は2024年までに97億米ドルに達すると予測されています。米国市場は、主に主要な医薬品の特許満了・ジェネリック医薬品の浸食により、他国の市場と比較して成長が緩やかになると見られています。

当レポートは、世界の点眼薬市場について調査し、今後の予測を提供しており、疾患の種類別による市場の動向・課題・規模・予測・薬剤、地域別の市場分析、治療薬のR&Dパイプラインおよび主要企業のプロファイルなどをまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 眼科疾患の病因・治療

  • 人間の目
  • 人間の目の構造
  • 失明・視力障害の主因
    • 失明の主因
    • 視力障害の主因
    • 世界における失明・視力障害の地域分析
    • 視力障害に関連する主因
  • 最も一般的な眼科疾患の種類
    • 白内障
    • 緑内障
    • 網膜はく離
    • 眼科アレルギー
    • 眼科炎症性疾患
    • 眼科感染症
    • 糖尿病性網膜症/糖尿病
    • ドライアイ
    • 加齢に伴う黄斑変性症

第3章 眼科医薬品市場・予測

  • 主要動向・課題
  • 世界の眼科医薬品市場

第4章 抗緑内障薬市場

  • 緑内障点眼薬の種類
  • 主要動向・課題
  • 市場規模・予測
  • 主要薬剤・予測

第5章 眼科抗アレルギー/炎症/感染薬市場

  • 緑内障点眼薬の種類
  • 主要動向・課題
  • 市場規模・予測
  • 主要薬剤・予測

第6章 網膜疾患市場

  • 主要動向・課題
  • 市場規模・予測
  • 主要薬剤・予測

第7章 ドライアイ市場

  • 主要動向・課題
  • 市場規模・予測
  • 主要薬剤・予測

第8章 地域別の情勢:世界の主ながん治療薬市場

  • 米国
  • 英国
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 日本
  • その他

第9章 眼科のR&Dパイプライン

  • 緑内障
  • 抗感染薬
  • 抗炎症薬
  • ドライアイ
  • 眼科における遺伝子療法 - 継続中の治験詳細

第10章 主要企業

  • Alcon
  • Allergan
  • Argentis Pharmaceuticals LLC
  • Bausch & Lomb
  • Bayer Healthcare Pharmaceuticals
  • Eagle Vision Inc.
  • Eyegate Pharmaceuticals
  • Merck & Co
  • Novagali Pharma
  • Oasis Medical Inc.
  • Pfizer
  • Regeneron Pharmaceuticals Inc.
  • Resolvyx Pharmaceuticals Inc.
  • Roche
  • Santen Pharmaceutical Co Ltd

第11章 専門家の見解

図表リスト

目次
Product Code: OPTH1

Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data's new 'Ophthalmic Drugs; Data, Analysis and Forecasts to 2024' report, you can stay ahead of your competition. It really is that simple.

GMR Data forecasts that the global ophthalmic drugs market will reach $9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example;

  • Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in March 2011.
  • Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012.
  • Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.
  • Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014.
  • Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014.
  • Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022.
  • Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020.

Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of $1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. With an assessment of the leading markets, such as the US, and EU, GMR Data examine how Germany and France are the largest EU markets and what % of the global market they make up. Which other countries contribute most? This report tells you in a concise, focused and easily accessible format.

But how will these country's markets develop? This report will tell you - TODAY

Global incidences of AMD, Glaucoma and Diabetic Retinopathy are all set to increase dramatically across the forecast period of 2014-2024; this will have the knock-on effect of driving sales of key drugs for treatment i.e. Lucentis and Eylea, as well as driving R&D. How much is being spent on R&D - and which drugs are likely to see a return? And how quickly?

Which new drugs will we see in the ophthalmic market across 2014-2024?

In December 2013 Santen announced that Ikervis (Ciclosporin / Cyclokat) was filed to the EMA, in doing so the EMA will begin its regulatory process. Diquas, which was launched in 2010 by Santen Pharma in Japan, China and other Asian markets, and despite US trials being unsuccessful, is expected to gain approval in the EU early in our forecast period.

Other key ophthalmic drugs currently under taking trials include;

  • Sirolimus (By Santen, in Phase III US)
  • Tafluprost/Timolol maleate (By Santen, filed for NDA)
  • Catioprost (By Santen in Phase 2)

PLUS - In-depth country analysis - Discover which countries and regions will drive the ophthalmic drugs market to 2024?

Exclusive Industry sourced information, not available anywhere else

As well as primary and secondary research sources, GMR Data have interviewed leading ophthalmic specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field - This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Ophthalmic Drugs. This report will arm you with all you and your company require to develop, price, launch and market an ophthalmic drug.

With over 150 pages, and over 140 charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Table of Contents

1. Executive Summary

  • 1.1 Ophthalmic Drugs Market Review
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods

2. Causes and Treatments of Ophthalmic Disorders

  • 2.1 Human Eye
  • 2.2 Structure of Human Eye
  • 2.3 Major Global Causes of Blindness & Vision Impairment
    • 2.3.1 Primary Causes of Blindness
    • 2.3.2 Primary Causes of Visual Impairment
    • 2.3.3 Geographic Breakdown of Global Blindness and Vision Impairment
    • 2.3.4 Primary Factors Contributing to Visual Impairment
  • 2.4 The Most Common Type of Eye Disorders
    • 2.4.1 Cataracts
    • 2.4.2 Glaucoma
    • 2.4.3 Retinal Detachment
    • 2.4.4 Ophthalmic Allergies
    • 2.4.5 Ophthalmic Inflammatory Disorders
    • 2.4.6 Ophthalmic Infections
    • 2.4.7 Diabetic Retinopathy/Diabetic Mellitus
    • 2.4.8 Dry Eye
    • 2.4.9 Age-related Macular Degeneration

3. Ophthalmology Pharmaceutical Market & Forecast

  • 3.1 Major Trends and Issues
  • 3.2 Global Ophthalmology Pharmaceuticals Market 2014-2024

4. Anti-Glaucoma Market 2014-2024

  • 4.1 Types of Glaucoma Eye Drops
  • 4.2 Major Trends and Issues
  • 4.3 Market Size and Forecast
  • 4.4 Major Drugs & Forecast
    • 4.4.1 Xalatan/Xalacom
    • 4.4.2 Lumigan
    • 4.4.3 Cosopt/Trusopt
    • 4.4.4 Alphagan P, Alphagan and Combigan
    • 4.4.5 Travatan
    • 4.4.6 Azopt

5. Ophthalmic Anti-Allergy/Inflammation/Infective Market 2014-2024

  • 5.1 Major Trends and Issues
  • 5.2 Market Size and Forecast
  • 5.3 Major Drugs and Forecast
    • 5.3.1 Patanol
    • 5.3.2 Vigamox/Vegamox
    • 5.3.3 TobraDex
    • 5.3.4 Pataday
    • 5.3.5 Cravit
    • 5.3.6 Xibrom/Bromday/Bromfenac

6. Retinal Disorders Market 2014-2024

  • 6.1 Major Trends and Issues
  • 6.2 Market Size and Forecast
  • 6.3 Major Drugs and Forecast
    • 6.3.1 Lucentis
    • 6.3.2 Eylea

7. Dry Eye Market 2014-2024

  • 7.1 Major Trends and Issues
  • 7.2 Market Size and Forecast
  • 7.3 Major Drugs and Forecast
    • 7.3.1 Restasis
    • 7.3.2 Hyalein

8. Regional Landscape

  • 8.1 The US Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.2 The UK Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.3 The French Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.4 The German Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.5 The Spanish Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.6 The Italian Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.7 The Japanese Ophthalmic Pharmaceutical Drugs Market 2013-2024
  • 8.8 The ROW Ophthalmic Pharmaceutical Drugs Market 2013-2024

9. Ophthalmology R & D Pipeline

  • 9.1 Ophthalmology Drug R&D Pipeline for Glaucoma
  • 9.2 Ophthalmology Drug R&D Pipeline for Anti-Infectives
  • 9.3 Ophthalmology Drug R&D Pipeline for Anti-Inflammatory Agents
  • 9.4 Ophthalmology Drug R&D Pipeline for Dry Eye
  • 9.5 Gene Therapy in Ophthalmology - Ongoing Clinical Trial Details

10. Leading Companies

  • 10.1 Alcon
  • 10.2 Allergan
  • 10.3 Argentis Pharmaceuticals LLC
  • 10.4 Bausch & Lomb
  • 10.5 Bayer Healthcare Pharmaceuticals
  • 10.6 Eagle Vision Inc.
  • 10.7 Eyegate Pharmaceuticals
  • 10.8 Merck & Co
  • 10.9 Novagali Pharma
  • 10.10 Oasis Medical Inc.
  • 10.11 Pfizer
  • 10.12 Regeneron Pharmaceuticals Inc.
  • 10.13 Resolvyx Pharmaceuticals Inc.
  • 10.14 Roche
  • 10.15 Santen Pharmaceutical Co Ltd

11. Expert Opinion

  • 11.1 Dr David Sullivan, Associate Professor at Harvard Medical School
  • 11.2 Dr Sonja Prager, Head of Diabetic Retinopathy Research Group, Vienna

List of Tables

  • Table 2.3 WHO Estimation of Blind/Vision impaired Population Globally, 1975-2010
  • Table 2.3.1 Breakdown of Global Blindness Cases as per Eye Disease
  • Table 2.3.2 Breakdown of Global Vision Impairment Cases as per Eye Disease 2010
  • Table 2.4.2.1 Major Glaucoma Drugs in the Market
  • Table 2.4.4.1 Major Ophthalmic Anti-allergy Drugs in the Market
  • Table 2.4.5.1 Major Ophthalmic Anti-inflammatory Drugs in the Market
  • Table 2.4.6.1 Major Ophthalmic Anti-infective Drugs in the Market
  • Table 2.4.7.1 Major Diabetic Retinopathy Drugs in the Market
  • Table 2.4.8.1 Major Dry Eye Treatment Drugs in the Market
  • Table 2.4.9.1 Major wet-AMD Treatment Drugs in the Market
  • Table 3.2.1 Global Ophthalmology Pharmaceutical Market 2014-2024 - Breakdown by Disease ($/bn)
  • Table 3.2.2 Market Size & Forecast - Global Ophthalmology Pharmaceutical Sales ($/bn)
  • Table 4.3.1 Global Anti-Glaucoma Market 2009-2013 ($/bn)
  • Table 4.3.2 Global Anti-Glaucoma Market 2014-2024 ($/bn)
  • Table 4.4.1.1 Xalatan/Xalacom Sales 2009-2013 ($/m)
  • Table 4.4.1.2 Xalatan/Xalacom Sales Forecast 2014-2024 ($/m)
  • Table 4.4.2.1 Lumigan Sales 2009-2013($/m)
  • Table 4.4.2.2 Lumigan Sales Forecast 2014-2024 ($/m)
  • Table 4.4.3.1 Cosopt/Trusopt Sales 2009-2013 ($/m)
  • Table 4.4.3.2 Cosopt/Trusopt Sales Forecast 2014-2024 ($/m)
  • Table 4.4.4.1 Alphagan P, Alphagan and Combigan Sales 2009-2013 ($/m)
  • Table 4.4.4.2 Alphagan P, Alphagan and Combigan Sales Forecast 2014-2024 ($/m)
  • Table 4.4.5.1 Travatan Sales 2009-2013 ($/m)
  • Table 4.4.5.2 Travatan Sales Forecast 2014-2024 ($/m)
  • Table 4.4.6.1 Azopt Market Size and Forecast 2012-2024 ($/m)
  • Table 5.1.1 ophthalmic Anti-Allergy/Inflammation/Infective R&D pipeline
  • Table 5.2.1 Global Ophthalmic Anti-Allergy/Inflammation/Infective Market 2013-2024 ($/bn)
  • Table 5.3.1.1 Patanol Market Size and Forecast 2012-2024 ($/m)
  • Table 5.3.2.1 Vigamox/Vegamox Market Size & Forecast 2012-2024 ($/m)
  • Table 5.3.3.1 TobraDex Market Size and Forecast 2012-2024 ($/m)
  • Table 5.3.4.1 Pataday Market Size and Forecast 2012-2024 ($/m)
  • Table 5.3.5.1 Cravit Sales 2009-2013 ($/m)
  • Table 5.3.5.2 Cravit Sales Forecast 2014-2024 ($/m)
  • Table 5.3.6.1 Xibrom/Bromday/Bromfenac Sales 2009-2013 ($/m)
  • Table 5.3.6.2 Xibrom/Bromday/Bromfenac Sales Forecast 2014-2024 ($/m)
  • Table 6.2.1 Global Anti-Retinal Disorders Drug Market 2009-2013 ($/bn )
  • Table 6.2.2 Global Anti-Retinal Disorders Drug Market 2014-2024 ($/bn)
  • Table 6.3.1.1 Lucentis Sales 2009-2013($/m)
  • Table 6.3.1.2 Lucentis Sales Forecast 2014-2024 ($/m)
  • Table 6.3.2.1 Eylea Market Size and Forecast 2012-2024 ($/m)
  • Table 7.2.1 Global Dry-Eye Market Size and Forecast 2012-2024 ($/bn)
  • Table 7.3.1.1 Restasis Sales 2009-2013 ($/m)
  • Table 7.3.1.2 Restasis Sales Forecast 2014-2024 ($/m)
  • Table 7.3.2.1 Hyalein Sales 2009-2013 ($/m)
  • Table 7.3.2.2 Hyalein Sales Forecast 2014-2024 ($/m)
  • Table 8.1 The Global Ophthalmic Drug Market Forecast 2013-2024, by country ($/bn per annum)
  • Table 8.2 Key Countries CAGR 2014-2024 (%)
  • Table 8.3 Global Ophthalmic Pharmaceutical Drugs Market Share for Major Countries - 2014, 2019, 2024
  • Table 8.4 Total Health Care Spending and Health Care Expenditure per Capita 2011 ($ per annum)
  • Table 8.1.1 US Ophthalmic Pharmaceutical Drugs Market Forecast 2013-2024
  • Table 8.1.2 Details of Major Ophthalmic Drugs in the US
  • Table 8.2.1 UK Ophthalmic Pharmaceutical Drugs Market Forecast 2013-2024
  • Table 8.3.1 French Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Table 8.4.1 German Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Table 8.5.1 Spanish Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Table 8.6.1 Italian Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Table 8.7.1 Japanese Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Table 8.8.1 ROW Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Table 8.8.2 BRIC Population, Healthcare Expenditure per Capita
  • Table 9.1 Ophthalmology Drug R&D Pipeline for Glaucoma
  • Table 9.2 Ophthalmology Drug R&D Pipeline for Anti-infective Agents
  • Table 9.3 Ophthalmology Drug R&D Pipeline for Anti-inflammatory Agents
  • Table 9.4 Ophthalmology Drug R&D Pipeline for Dry Eye
  • Table 9.5 Gene Therapy in Ophthalmology - Ongoing Clinical Trial Details
  • Table 10.1.1 Alcon Sales 2010-2012
  • Table 10.1.2 Sales of Major Ophthalmic Drugs
  • Table 10.1.3 Product Categories by Ophthalmic Pharmaceuticals
  • Table 10.2.1 Allergan Sales 2010-2012 (Eye care Pharmaceuticals)
  • Table 10.2.2 Allergan's Key Ophthalmic Drug Sales 2012 ($/m)
  • Table 10.2.3 Allergan's Key Ophthalmic Drugs Portfolio 2014
  • Table 10.2.4 Allergan's Product Pipeline; Eye Care 2014
  • Table 10.3.1 Argentis Product Pipeline for Dry eye
  • Table 10.4.1 Bausch & Lomb Key Ophthalmic Drugs Portfolio 2014
  • Table 10.5.1 Bayer's Ophthalmic Products Overview 2014
  • Table 10.5.2 Bayer's Product Pipeline; Eye Care 2014
  • Table 10.6.1 Eagle Vision Key Ophthalmic Drugs Portfolio 2014
  • Table 10.7.1 Eyegate Product Pipeline; Eye Care 2014
  • Table 10.8.1 Merck & Co Key Ophthalmic Drugs Portfolio 2014
  • Table 10.8.2 Merck & Co Product Pipeline; Eye Care 2014
  • Table 10.9.1 Novagali Pharma Ophthalmic Drugs Portfolio 2014
  • Table 10.9.2 Novagali Pharma Product Pipeline; Eye Care 2014
  • Table 10.10.1 Oasis Medical Ophthalmic Drugs Portfolio 2014
  • Table 10.11.1 Pfizer Pharmaceuticals Ophthalmic Drugs Portfolio 2014
  • Table 10.12.1 Regeneron Pharmaceuticals Ophthalmic Drugs Portfolio 2014
  • Table 10.12.2 Regeneron Pharmaceuticals Product Pipeline; Eye Care 2014
  • Table 10.13.1 Resolvyx Pharmaceuticals Product Pipeline; Eye Care 2014
  • Table 10.14.1 Roche Ophthalmology Ophthalmic Drugs Portfolio 2014
  • Table 10.14.2 Roche Ophthalmology Product Pipeline; Eye Care 2014
  • Table 10.15.1 Santen Pharmaceuticals Ophthalmic Drugs Portfolio 2014
  • Table 10.15.2 Santen Pharmaceuticals Product Pipeline; Eye Care 2014

List of Figures

  • Figure 2.3 WHO Estimation of Blind/Vision impaired Population Globally, 1975-2010
  • Figure 2.3.1 Breakdown of Global Blindness Cases, as per Eye Disease, 2010
  • Figure 2.3.2 Breakdown of Global Vision Impairment Cases as per Eye Disease 2010
  • Figure 2.3.3 Breakdown of Global Blindness and Vision Impairment by Geography 2012
  • Figure 2.3.4 Projection of Global Blind People aged 50+ by 2019
  • Figure 3.2.1 Market Size and Forecast - Global Ophthalmology Pharmaceuticals Sales ($/m)
  • Figure 3.2.2 Global Ophthalmology Pharmaceuticals Drug Market Share 2014 to 2024 - (%)
  • Figure 4.2.1 Population of over 60's in Selected Nations 2009 (millions)
  • Figure 4.2.2 Market Share of Major Companies - by Sales of Anti-Glaucoma Drug 2012
  • Figure 4.3.1 Global Anti-Glaucoma Market 2009-2013 ($/bn)
  • Figure 4.3.2 Global Anti-Glaucoma Market 2014-2024 ($/bn)
  • Figure 4.4.1.1 Xalatan/Xalacom Sales 2009-2013 ($/m)
  • Figure 4.4.1.2 Xalatan/Xalacom Sales Forecast 2014-2024 ($/m)
  • Figure 4.4.2.1 Lumigan Sales 2009-2013 ($/m)
  • Figure 4.4.2.2 Lumigan Sales Forecast 2014-2024 ($/m)
  • Figure 4.4.3.1 Cosopt/Trusopt Sales 2009-2013 ($/m)
  • Figure 4.4.3.2 Cosopt/Trusopt Sales Forecast 2014-2024($/m)
  • Figure 4.4.4.1 Alphagan P, Alphagan and Combigan Sales 2009-2013 ($/m)
  • Figure 4.4.4.2 Alphagan P, Alphagan and Combigan Sales 2014-2024 ($/m)
  • Figure 4.4.5.1 Travatan Sales 2009-2014 ($/m)
  • Figure 4.4.5.2 Travatan Sales Forecast 2014-2024 ($/m)
  • Figure 4.4.6.1 Azopt Market Size and Forecast 2012-2024 ($/m)
  • Figure 5.2.2 Global Ophthalmic Anti-Allergy/Inflammation/Infective Market 2013-2024 ($/bn)
  • Figure 5.3.1.1 Patanol Market Size & Forecast 2012-2024 ($/m)
  • Figure 5.3.2.1 Vigamox/Vegamox Market Size & Forecast 2012-2024 ($/m)
  • Figure 5.3.3.1 TobraDex Market Size & Forecast 2012-2024 ($/m)
  • Figure 5.3.4.1 Pataday Market Size & Forecast 2012-2024 ($/m)
  • Figure 5.3.5.1 Cravit Sales 2009-2013 ($/m)
  • Figure 5.3.5.2 Cravit Sales Forecast 2014-2024 ($/m)
  • Figure 5.3.6.1 Xibrom/Bromday/Bromfenac Sales 2009-2013 ($/m)
  • Figure 5.3.6.2 Xibrom/Bromday/Bromfenac Sales Forecast 2014-2024 ($/m)
  • Figure 6.2.1 Population of over 60's in Selected Nations 2009 (millions)
  • Figure 6.2.2 Global Anti-Retinal Disorders Drug Market 2009-2013 ($/bn)
  • Figure 6.2.3 Global Anti-Retinal Disorders Drug Market 2014-2024 ($/bn)
  • Figure 6.3.1.1 Lucentis Sales 2009-2013 ($/m)
  • Figure 6.3.1.2 Lucentis Sales Forecast 2014-2024 ($/m)
  • Figure 6.3.2.1 Geographic Breakdown of Eylea Sales in US and ROW 2012/13
  • Figure 6.3.2.2 Eylea Market Size and Forecast 2012-2024 ($/m)
  • Figure 7.2.1 Global Dry-Eye Drug Market 2012-2024 ($/bn)
  • Figure 7.3.1.1 Restasis Sales 2009-2013 ($/m)
  • Figure 7.3.1.2 Restasis Sales Forecast 2014-2024 ($/m)
  • Figures 7.3.2.1 Hyalein Sales 2009-2013 ($/m)
  • Figure 7.3.2.2 Hyalein Sales Forecast 2014-2024 ($/m)
  • Figure 8.1 Global Ophthalmic Drug Market Share for Major Countries - 2014, 2019, 2024
  • Figure 8.1.1 US Ophthalmic Pharmaceutical Drugs Market Forecast 2013-2024 ($/bn)
  • Figure 8.2.1 UK Ophthalmic Pharmaceutical Drugs Market Forecast 2013-2024 ($/bn)
  • Figure 8.3.1 French Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Figure 8.4.1 German Ophthalmic Pharmaceutical Drugs Market Forecast 2013-2024 ($/bn)
  • Figure 8.5.1 Spanish Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Figure 8.6.1 Italian Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Figure 8.7.1 Japanese Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Figure 8.8.1 ROW Ophthalmic Pharmaceutical Drug Market Forecast 2013-2024 ($/bn)
  • Figure 10.1.1 Alcon Sales by Segments 2012 (%)
  • Figure 10.1.2 Surgical Segments Sales Breakdown 2012
  • Figure 10.1.3 Ophthalmic Pharmaceutical Segment Sales Breakdown 2012
  • Figure 10.1.4 Vision Care segment Sales Breakdown 2012
  • Figure 10.1.5 Alcon Sales Breakdown by Geography 2012
Back to Top